Table 1.

Clinical information

Patient	Age	Sex	FCD location	Last sz prior to scan (days)	AEDs	Age at sz onset/duration of epilepsy (years)	Surgery follow-up (years), Engel class	Pathology	PET scanner
1	39	F	L lateral frontal	180	LEV, LMT, CLB, CBZ	3/36	No	N/A	HR+
2	56	M	R mesial parietal/posterior cingulate	1	CBZ, LEV, CLB	8/48	6 y, Engel I	FCD IIb	HR+
3	25	M	R superior temporal	4	CBZ	8/17	6 y9 m, Engel I	FCD IIb	HRRT
4	20	F	L superior temporal	1	CLB	14/6	No	N/A	HRRT
5	19	F	R parahippocampal	11	VA, LEV, PB	15/4	6 y11 m, Engel II	FCD IIa	HR+
6	31	F	L posterior cingulate/mesial parietal	1	LMT, DPH, CLB	16/15	No	N/A	HR+
7	39	F	L mesial orbitofrontal	30	None (LMT discontinued at admission)	34/5	No	N/A	HR+
8	29	M	R frontal pole	1	VA, OXC, CLB	0.4/29	4 y3 m, Engel I	FCD IIb	HRRT
9	41	F	L posterior fusiform gyrus	6	LMT, PB, CLB	12/29	No	N/A	HR+
10	38	M	R inferior frontal	1	CBZ, CLB	17/21	5 y1 m, Engel I	FCD IIb	HRRT

F, female; M, male; L, left; R, right; sz, seizure; AED, antiepileptic drug; LEV, levetiracetam, LMT, lamotrigine; CBZ, carbamazepine; CLB, clobazam; DPH, diphenylhydantoine; VA, valproic acid; OXC, oxcarbazepine; PB, phenobarbital.